Effects of reduced cigarette smoking on levels of 1-hydroxypyrene in urine

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 5, 2004, Pages 834-842

  Hecht, Stephen S ^a,b   Carmella, Steven G ^a   Le, Ky Anh ^a   Murphy, Sharon E ^a   Shelby Li, Y ^a   Le, Chap ^a   Jensen, Joni ^a   Hatsukami, Dorothy K ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 HYDROXYPYRENE; BIOLOGICAL MARKER; CARCINOGEN; POLYCYCLIC AROMATIC HYDROCARBON; PYRENE;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; SMOKING HABIT; UNITED STATES; URINALYSIS;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; POLYCYCLIC HYDROCARBONS, AROMATIC; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SMOKING; SMOKING CESSATION; STATISTICS, NONPARAMETRIC;

EID: 2942602686     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004,54:8-29.
2. IARC. Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon, France: IARC; 2003.
3. Cigarette smoking among adults-United States. Morb Mortal Wkly Rep 2002;51:642-5.
4. Mackay J, Eriksen M. The Tabacco Atlas. Geneva: World Health Organization; 2002. p. 30-31.
5. IARC. Polynuclear aromatic compounds, part 3. Industrial exposures in aluminum production, coal gasification, coke production, and iron and steel founding. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Lyon, France: IARC; 1984. p. 65-131.
6. IARC. Polynuclear aromatic compounds, part 4. Bitumens, coal-tars and derived products, shale oils and soots. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Lyon, France: IARC; 1985. p. 83-241.
7. IARC. Tobacco smoking. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Lyon, France: IARC; 1986. p. 91-120.
8. IARC. Polynuclear aromatic compounds, part 1. Chemical, environmental, and experimental data. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Lyon, France: IARC; 1983. p. 33-451.
9. Hoffmann D, Hecht SS. Advances in tobacco carcinogenesis. In: Cooper CS, Grover PL, editors. Handbook of experimental pharmacology. Heidelberg: Springer-Verlag; 1990. p. 63-102.
10. Boysen G, Hecht SS. Analysis of DNA and protein adducts of benzo(a) pyrene in human tissues using structure-specific methods. Mutat Res 2003;543:17-30.
11. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002;21:7435-51.
12. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210.
13. Phillips DH. Smoking-related DNA and protein adducts in human tissues. Carcinogenesis 2002;23:1979-2004.
14. Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002;23:907-22.
15. Jongeneelen FJ. Benchmark guideline for urinary 1-hydroxypyrene as biomarker of occupational exposure to polycyclic aromatic hydrocarbons. Ann Occup Hyg 2001;45:3-13.
16. Jacob J, Seidel A. Biomonitoring of polycyclic aromatic hydrocarbons in human urine. J Chromatogr B 2002;778:31-47.
17. Jacob P III, Hatsukami D, Severson H, Hall S, Yu L, Benowitz NL. Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiol Biomarkers & Prev 2002;11:1668-73.
18. Hecht SS, Carmella SG, Chen M, et al. Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res 1999;59:590-6.
19. Carmella SG, Le K, Hecht SS. Improved method for determination of 1-hydroxypyrene in human urine. Cancer Epidemiol Biomarkers & Prev 2004. In press.
20. Davis CS. Statistical methods for the analysis of repeated measurements. New York: Springer-Verlag; 2002.
21. Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov BN, Czaki F. editors. Second international symposium on information theory. Budapest: Akademiai Kiado; 1973. p. 267-81.
22. Viau C, Diakite A, Ruzgyte A, et al. Is 1-hydroxypyrene a reliable bioindicator of measured dietary polycyclic aromatic hydrocarbon under normal conditions? J Chromatogr B 2002;778:165-77.
23. Angerer J, Mannschreck C, Gundel J. Biological monitoring and biochemical effect monitoring of exposure to polycyclic aromatic hydrocarbons. Int Arch Occup Environ Health 1997;70:365-77.
24. Jongeneelen FJ. Biological monitoring of environmental exposure to polycyclic aromatic hydrocarbons; 1-hydroxypyrene in urine of people. Toxicol Lett 1994;72:205-11.
25. Scherer G. Smoking behavior and compensation: a review of the literature. Psychopharmacology (Berl) 1999;145:1-20.
26. Djordjevic MV, Stellman SD, Zang E. Doses of nicotine and lung carcinogens delivered to cigarette smokers. J Natl Cancer Inst 2000;92:106-11.
27. Benowitz NL, Jacob III, Kozlowski LT, Yu L. Influence of smoking fewer cigarettes on exposure to tar, nicotine, and carbon monoxide. N Engl J Med 1986;315:1310-3.
28. Fagerstrom KO, Hughes JR. Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: a review. Nicotine Tob Res 2002;4(Suppl 2):S73-9.
29. Hurt RD, Croghan GA, Wolter TD, et al. Does smoking reduction result in reduction of biomarkers associated with harm? A pilot study using a nicotine inhaler. Nicotine Tob Res 2000;2:327-36.
30. Hecht SS, Murphy SE, Carmella SG, et al. Effects of reduced cigarette smoking on uptake of a tobacco-specific lung carcinogen. J Natl Cancer Inst 2004,96:107-15.